DiaMedica Therapeutics

DMAC · NASDAQ

$8.67+$0.80 (+10.17%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.87

Latest news

Press releaseOct 19, 8:00 AM ETBusiness Wire
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
Press releaseSep 30, 8:30 AM ETBusiness Wire
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
Press releaseSep 2, 8:30 AM ETBusiness Wire
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
Press releaseAug 10, 4:30 PM ETBusiness Wire
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Press releaseAug 4, 4:30 PM ETBusiness Wire
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
Press releaseJul 17, 4:30 PM ETBusiness Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 23, 8:30 AM ETBusiness Wire
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
Press releaseJun 16, 8:30 AM ETBusiness Wire
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Press releaseMay 27, 4:30 PM ETBusiness Wire
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
Press releaseMay 20, 8:30 AM ETBusiness Wire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Press releaseMay 12, 4:15 PM ETBusiness Wire
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:30 PM ETBusiness Wire
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Press releaseApr 30, 8:25 AM ETBusiness Wire
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
Press releaseMar 30, 4:45 PM ETBusiness Wire
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
NewsMar 30, 7:11 AM ET
Earnings Scheduled For March 30, 2026
NewsMar 30, 4:56 AM ETAvi Kapoor
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
Press releaseMar 23, 8:25 AM ETBusiness Wire
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
NewsMar 5, 7:38 AM ET
DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia
Press releaseMar 5, 7:35 AM ETBusiness Wire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
Press releaseFeb 24, 9:23 AM ETBusiness Wire
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
Press releaseJan 16, 5:00 PM ETBusiness Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseDec 18, 8:45 AM ETBusiness Wire
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
NewsNov 14, 4:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseNov 12, 4:30 PM ETBusiness Wire
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
NewsNov 11, 10:06 AM ET
An Overview of DiaMedica Therapeutics's Earnings
Press releaseNov 10, 8:15 AM ETBusiness Wire
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Press releaseNov 6, 4:15 PM ETBusiness Wire
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
Press releaseSep 29, 4:15 PM ETBusiness Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseSep 5, 8:30 AM ETBusiness Wire
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
Press releaseSep 2, 8:23 AM ETBusiness Wire
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
NewsAug 18, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsMay 12, 4:09 PM ET
Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings
NewsNov 12, 1:13 PM ET
Preview: DiaMedica Therapeutics's Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Earnings Scheduled For May 6, 2026

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Earnings Scheduled For March 30, 2026

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

12 Health Care Stocks Moving In Friday's After-Market Session

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

An Overview of DiaMedica Therapeutics's Earnings

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

12 Health Care Stocks Moving In Monday's After-Market Session

Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings

Preview: DiaMedica Therapeutics's Earnings